Study finds Botox cuts pediatric chronic migraine headaches
A prospective study led by researchers at Children's National found that onabotulinumtoxinA (ONA), commonly known as Botox, reduces headache frequency and headache-related disability in children and young adults with chronic migraine, providing important evidence to support its use in a pediatric population where treatment options remain limited.
A new study has found that Botox injections can significantly reduce the frequency of headaches and their impact on daily life in children and young adults with chronic migraine. Conducted by researchers at Children's National, the prospective study followed 45 patients aged 12-22 who received ONA injections using the PREEMPT-2 protocol at the Headache Clinic.
Although FDA-approved for adults, Botox has not been approved for pediatric use due to a lack of evidence and insurance coverage challenges. The research demonstrates that ONA not only reduces the number of headache days by up to 50% after one treatment but also improves headaches-related disability, measured by the Headache Impact Test (HIT-6), leading to improved daily functioning and quality of life.
The study's lead author, Dr. Jeffrey Strelzik, emphasizes that these findings provide important evidence supporting the use of Botox in pediatric patients, addressing an urgent evidence gap and offering a potential treatment option for children with chronic migraine, including those experiencing daily headaches. The study's authors call for further research to identify which patients are most likely to benefit and to build a stronger evidence base to improve access to this treatment for children with chronic migraine.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
